Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Association of serum adropin with risk and severity of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus

The Egyptian Journal of Internal Medicine volume 31, pages 856–867 (2019)Cite this article

Abstract

Background

Diabetic peripheral neuropathy (DPN) is the major microvascular complication of type 2 diabetes mellitus (T2DM). Adropin is a peptide hormone that has essential roles in metabolic homeostasis and the pathogenesis of T2DM and its complications. This study was designed to estimate serum adropin levels in patients with T2DM in correlation with risk factors of DPN. The authors also aimed to investigate the association between serum adropin level and clinical and electrophysiological tests of DPN.

Patients and methods

This case–control study enrolled 100 patients with T2DM (40 diabetic cases without DPN and 60 diabetic cases with DPN) and 50 controls. All participants were subjected to a complete neurological examination. The motor and sensory conduction velocities of the median nerve, ulnar nerve, and common peroneal nerve were measured. The severity of DPN was assessed by Toronto clinical scoring system (TCSS). Serum adropin levels were assessed using an enzyme-linked immunosorbent assay.

Results

Our results revealed decreased circulating serum adropin levels in patients with T2DM (3.5±1.2), especially diabetic patients with DPN (3.1±1.07), compared with controls (6.1±0.89). There is a negative correlation between serum adropin level and TCSS as well as electrophysiological tests: motor nerve conduction velocity of median and ulnar nerve, sensory nerve conduction velocity of median and ulnar nerve, compound muscle action potential amplitude (median and ulnar nerve), and sensory nerve action potential amplitude (median, ulnar, and perception threshold nerve) (P<0.001*).

Conclusion

Diabetic patients with DPN had lower values of serum adropin than diabetic patients without DPN, and serum adropin levels were negatively correlated with metabolic risk factors, TCSS, as well as electrophysiological tests of DPN.

References

  1. American Diabetes Association. Microvascular complications and foot care. Diabetes Care 2016; 39:S72–S80.

    Article  Google Scholar 

  2. Wang W-T., Lee P, Yeh H-W., Smirnova IV, Choi I-Y. Effects of acute and chronic hyperglycemia on the neurochemical profiles in the rat brain with streptozotocin-induced diabetes detected using in vivo 1H MR spectroscopy at 9. 4 T. J Neurochem 2012; 121:407–417.

    Article  CAS  Google Scholar 

  3. Negi G, Kumar A, Joshi RP, Ruby PK, Sharma SS. Oxidative stress and diabetic neuropathy: current status of antioxidants. Inst Integrative Omics Appl Biotechnol J 2011; 2:71–78.

    CAS  Google Scholar 

  4. Bandeira SDM, da Fonseca LJS, Guedes GDS, Rabelo LA, Goulart MOF, Vasconcelos SML. Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus. Int J Mol Sci 2013; 14:3265–3284.

    Article  CAS  Google Scholar 

  5. Cox AA, Sagot Y, Hedou G, Grek C, Wilkes T, Vinik AI, Ghatnekar G. Low-dose pulsatile interleukin-6 as a treatment option for diabetic peripheral neuropathy. Front Endocrinol (Lausanne) 2017; 8:89.

    Article  Google Scholar 

  6. Aydin S, Kuloglu T, Aydin S, Eren MN, Yilmaz M, Kalayci M, et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocininduced diabetes. Mol Cell Biochem 2013; 380:73–81.

    Article  CAS  Google Scholar 

  7. Gao S, McMillan RP, Zhu Q, Lopaschuk GD, Hulver MW, Butler AA. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab 2015; 4:4.

    Article  Google Scholar 

  8. Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008; 8:468–481.

    Article  CAS  Google Scholar 

  9. Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med 2014; 52:751–758.

    CAS  PubMed  Google Scholar 

  10. Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med 2013; 61:1161–1164.

    Article  CAS  Google Scholar 

  11. Meijer WG, Bosma E, Lefrandt JD, Links TP, Smit AJ, Stewart RE, et al. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. Diabetes Care 2003; 26:697–701.

    Article  Google Scholar 

  12. Sachedina S, Toth C. Association of comorbidities with increasing severity of peripheral neuropathy in diabetes mellitus. World J Diabetes 2013; 4:135–144.

    Article  Google Scholar 

  13. Dyck PJ, Carter RE, Litchy WJ. Modeling nerve conduction criteria for diagnosis of diabetic polyneuropathy. Muscle Nerve 2011; 44:340–345.

    Article  Google Scholar 

  14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499–502.

    Article  CAS  Google Scholar 

  15. Yang C, DE-Mars KM, Hawkins KE, Candelario-Jalil E. Adropin reduces paracellular permeability of rat brain endothelial cells exposed to ischemia like conditions. Peptides 2016; 81:29–37.

    Article  CAS  Google Scholar 

  16. Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012; 28(Suppl 1):8–14.

    Article  Google Scholar 

  17. Callaghan BC, Cheng HT, Stables CL, Andrea L, Smith AL, Feldman EL. Dia? betic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012; 11:521–534.

    Google Scholar 

  18. Papanas N, Ziegler D. Prediabetic neuropathy: does it exist? Curr Diabetes Rep 2012; 12:376–383.

    Article  Google Scholar 

  19. Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuroropathy. Diabet Med 1998; 15:508–514.

    Article  CAS  Google Scholar 

  20. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001; 285:2486–2497.

  21. Wu SC, Driver VR, Wrobel JS, Armstrong DG. Foot ulcers in the diabetic patient, prevention and treatment. Vasc Health Risk Manag 2007; 3:65–76.

    PubMed  PubMed Central  Google Scholar 

  22. Boulton AJ, Vinik AI, Arezzo JC, Feldman EL, Freeman R, Malik RA, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28:956–962.

    Article  Google Scholar 

  23. Khawaja N, Abu-Shennar J, Saleh M, Dahbour SS, Khader YS, Ajlouni KM. HY The prevalence and risk factors of peripheral neuropathy among patients with type 2 diabetes mellitus; the case of Jordan. Diabetol Metab Syndr 2018; 10:8.

    Article  Google Scholar 

  24. Dyck PJ, Davies JL, Clark VM, Litchy WJ, Klein CJ, et al. Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care 2006; 29:2282–2288.

    Article  Google Scholar 

  25. Ylitalo KR, Sowers M, Heeringa S. Peripheral vascular disease and peripheral neuropathy in individuals with Cardiometabolic Clustering and Obesity National Health and Nutrition Examination Survey 2001–2004. Diabetes Care 2011; 34:1642–1647.

    Article  Google Scholar 

  26. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008; 31:464–469.

    Article  CAS  Google Scholar 

  27. Tapp RJ, Shaw JE, de Courten MP, Dunstan DW, Welborn TA, et al. Foot complications in type 2 diabetes: an Australian population-based study. Diabet Med 2003; 20:105–113.

    Article  CAS  Google Scholar 

  28. Morkrid K, Ali L, Hussain A. Risk factors and prevalence of diabetic peripheral neuropathy: A study of type 2 diabetic outpatients in Bangladesh. Int J Diabetes Dev Ctries 2010; 30:11–17.

    Article  Google Scholar 

  29. Sone H, Mizuno S, Yamada N. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352:1925–1927.

    Article  Google Scholar 

  30. Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, et al. Risk factors for diabetic peripheral sensory neuropathy: results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 1997; 20:1162–1167.

    Article  CAS  Google Scholar 

  31. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, et al. Epidemiological correlates of diabetic neuropathy: report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989; 38:1456–1461.

    Article  CAS  Google Scholar 

  32. Gao S, McMillan RP, Zhu Q, Lopaschuk GD, Hulver MW, Butler AA. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab 2015; 4:310–324.

    Article  CAS  Google Scholar 

  33. Beigi A, Shirzad N, Nikpour F, Nasli Esfahani E, Emamgholipour S, Bandarian F. Association between serum adropin levels and gestational diabetes mellitus; a case-control study. Gynecol Endocrinol 2015; 31:939–941.

    Article  CAS  Google Scholar 

  34. Hu W, Chen L. Association of serum adropin concentrations with diabetic nephropathy mediators of inflammation. Mediators of Inflammation 2016; 2016:1–5. DOI: 10.1155/2016/6038261

    Google Scholar 

  35. Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity 2012; 20:1394–1402.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt

    Nearmeen M. Rashad MD & Samir A. Afifi

  2. Department of Neurology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Hanan M. Sabry

  3. Department of Physiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Maha A. Fathy

Authors
  1. Nearmeen M. Rashad MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanan M. Sabry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samir A. Afifi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maha A. Fathy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nearmeen M. Rashad MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rashad, N.M., Sabry, H.M., Afifi, S.A. et al. Association of serum adropin with risk and severity of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus. Egypt J Intern Med 31, 856–867 (2019). https://doi.org/10.4103/ejim.ejim_130_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_130_19

Keywords